S&P 500   3,956.81 (+0.58%)
DOW   33,696.63 (+0.29%)
QQQ   282.90 (+0.84%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,956.81 (+0.58%)
DOW   33,696.63 (+0.29%)
QQQ   282.90 (+0.84%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,956.81 (+0.58%)
DOW   33,696.63 (+0.29%)
QQQ   282.90 (+0.84%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
S&P 500   3,956.81 (+0.58%)
DOW   33,696.63 (+0.29%)
QQQ   282.90 (+0.84%)
AAPL   141.98 (+0.74%)
MSFT   246.69 (+0.95%)
META   115.51 (+1.39%)
GOOGL   94.03 (-0.96%)
AMZN   89.79 (+1.50%)
TSLA   172.39 (-0.95%)
NVDA   169.16 (+4.94%)
NIO   13.32 (+5.88%)
BABA   94.02 (+6.44%)
AMD   69.77 (-0.53%)
T   19.12 (-0.93%)
MU   55.14 (+2.45%)
CGC   2.99 (-7.72%)
F   13.11 (+0.08%)
GE   83.24 (-2.07%)
DIS   92.34 (+0.21%)
AMC   6.14 (+1.49%)
PYPL   74.22 (-0.27%)
PFE   51.68 (+2.87%)
NFLX   308.23 (-0.06%)
NASDAQ:BLCM

Bellicum Pharmaceuticals - BLCM Stock Forecast, Price & News

$1.05
+0.09 (+9.38%)
(As of 12/8/2022 01:45 PM ET)
Add
Compare
Today's Range
$1.01
$1.06
50-Day Range
$0.94
$1.25
52-Week Range
$0.93
$2.20
Volume
565 shs
Average Volume
6,509 shs
Market Capitalization
$9.04 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$5.00

Bellicum Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
376.2% Upside
$5.00 Price Target
Short Interest
Healthy
1.50% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.99mentions of Bellicum Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.54) to ($1.13) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.35 out of 5 stars

BLCM stock logo

About Bellicum Pharmaceuticals (NASDAQ:BLCM) Stock

Bellicum Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers and solid tumors in the United States and internationally. The company's clinical product candidates include BPX-601, an autologous GoCAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of solid tumors expressing the prostate stem cell antigen; and BPX-603, a dual-switch GoCAR-T product candidate that is in Phase 1/2 clinical trials to treat solid tumors that express the human epidermal growth factor receptor 2 antigens. Its clinical product candidates also include Rivo-cel, an allogeneic T cell product candidate intended to enhance outcomes in the treatment of leukemias, lymphomas, and inherited blood disorders. It has collaboration and license agreements with Adaptimmune Therapeutics plc; Agensys, Inc.; BioVec Pharma, Inc.; ARIAD Pharmaceuticals, Inc.; and Baylor College of Medicine. Bellicum Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in Houston, Texas.

Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Stock News Headlines

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Short Interest Update
BLCM Bellicum Pharmaceuticals, Inc.
See More Headlines
Receive BLCM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bellicum Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

BLCM Company Calendar

Last Earnings
8/11/2021
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/23/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BLCM
Fax
N/A
Employees
7
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$5.00
High Stock Price Forecast
$5.00
Low Stock Price Forecast
$5.00
Forecasted Upside/Downside
+376.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-9,700,000.00
Pretax Margin
-1,082.27%

Debt

Sales & Book Value

Annual Sales
$6.20 million
Book Value
$2.90 per share

Miscellaneous

Free Float
7,726,000
Market Cap
$9.04 million
Optionable
Optionable
Beta
1.24

Key Executives

  • Mr. Richard A. Fair (Age 53)
    Pres, CEO & Director
    Comp: $915.28k
  • Ms. Charity D. Scripture M.S. (Age 47)
    Pharm.D., Chief Devel. Officer
    Comp: $226.23k
  • Mr. Charles S. Grass (Age 62)
    Principal Accounting Officer
  • Mr. Joseph Senesac (Age 52)
    Sr. VP of Technical Operations & Quality
  • Dr. Alan K. Smith Ph.D. (Age 64)
    Chief Scientific Officer
  • Dr. Aaron E. Foster (Age 49)
    Head of Research & Sr. VP













BLCM Stock - Frequently Asked Questions

Should I buy or sell Bellicum Pharmaceuticals stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bellicum Pharmaceuticals in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BLCM shares.
View BLCM analyst ratings
or view top-rated stocks.

What is Bellicum Pharmaceuticals' stock price forecast for 2023?

1 Wall Street research analysts have issued 12-month target prices for Bellicum Pharmaceuticals' shares. Their BLCM share price forecasts range from $5.00 to $5.00. On average, they anticipate the company's stock price to reach $5.00 in the next twelve months. This suggests a possible upside of 420.8% from the stock's current price.
View analysts price targets for BLCM
or view top-rated stocks among Wall Street analysts.

How have BLCM shares performed in 2022?

Bellicum Pharmaceuticals' stock was trading at $1.49 at the beginning of 2022. Since then, BLCM shares have decreased by 35.6% and is now trading at $0.96.
View the best growth stocks for 2022 here
.

Are investors shorting Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals saw a decrease in short interest in November. As of November 15th, there was short interest totaling 129,300 shares, a decrease of 7.1% from the October 31st total of 139,200 shares. Based on an average daily volume of 14,300 shares, the days-to-cover ratio is presently 9.0 days.
View Bellicum Pharmaceuticals' Short Interest
.

When is Bellicum Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our BLCM earnings forecast
.

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) posted its earnings results on Wednesday, August, 11th. The biopharmaceutical company reported ($0.22) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $1.15. The biopharmaceutical company had revenue of $0.70 million for the quarter.

When did Bellicum Pharmaceuticals' stock split?

Bellicum Pharmaceuticals shares reverse split before market open on Thursday, February 6th 2020. The 1-10 reverse split was announced on Wednesday, February 5th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, February 5th 2020. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Bellicum Pharmaceuticals own?
When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

How do I buy shares of Bellicum Pharmaceuticals?

Shares of BLCM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Bellicum Pharmaceuticals' stock price today?

One share of BLCM stock can currently be purchased for approximately $0.96.

How much money does Bellicum Pharmaceuticals make?

Bellicum Pharmaceuticals (NASDAQ:BLCM) has a market capitalization of $8.27 million and generates $6.20 million in revenue each year. The biopharmaceutical company earns $-9,700,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis.

How can I contact Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals' mailing address is 2130 WEST HOLCOMBE BOULEVARD SUITE 800, HOUSTON TX, 77030. The official website for the company is www.bellicum.com. The biopharmaceutical company can be reached via phone at (832) 384-1100 or via email at robert.uhl@westwicke.com.

This page (NASDAQ:BLCM) was last updated on 12/8/2022 by MarketBeat.com Staff